Nisa Investment Advisors
EDIT icon

Nisa Investment Advisors’s Editas Medicine EDIT Stock Holding History

Nisa Investment Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.02K Hold
932
– – ﹤0.01% 2690
2026
Q1 		$2.3K Hold
932
– – ﹤0.01% 2595
2025
Q4 		$1.91K Hold
932
– – ﹤0.01% 2614
2025
Q3 		$3.23K Hold
932
– – ﹤0.01% 2527
2025
Q2 		$2.05K Sell
932
-1,314
-59% -$2.15K ﹤0.01% 2600
2025
Q1 		$2.6K Buy
2,246
+237
+12% +$349 ﹤0.01% 2397
2024
Q4 		$2.55K Buy
2,009
+474
+31% +$1.21K ﹤0.01% 2417
2024
Q3 		$5.23K Sell
1,535
-311
-17% -$1.35K ﹤0.01% 2218
2024
Q2 		$8.62K Buy
1,846
+328
+22% +$1.85K ﹤0.01% 2190
2024
Q1 		$11.3K Buy
1,518
+123
+9% +$1.02K ﹤0.01% 2019
2023
Q4 		$14.1K Buy
1,395
+10
+0.7% +$88 ﹤0.01% 1964
2023
Q3 		$10.8K Sell
1,385
-24
-2% -$206 ﹤0.01% 2158
2023
Q2 		$11.6K Sell
1,409
-1,056
-43% -$9.2K ﹤0.01% 2232
2023
Q1 		$18K Sell
2,465
-675
-21% -$6K ﹤0.01% 2032
2022
Q4 		$28K Sell
3,140
-31
-1% -$340 ﹤0.01% 1950
2022
Q3 		$40K Sell
3,171
-29
-0.9% -$452 ﹤0.01% 1823
2022
Q2 		$38K Sell
3,200
-15,600
-83% -$209K ﹤0.01% 1824
2022
Q1 		$358K Sell
18,800
-310
-2% -$5.76K ﹤0.01% 1179
2021
Q4 		$364K Sell
19,110
-123
-0.6% -$4.23K ﹤0.01% 1097
2021
Q3 		$790K Sell
19,233
-1,728
-8% -$94.7K ﹤0.01% 983
2021
Q2 		$1.19M Sell
20,961
-850
-4% -$31.4K 0.01% 878
2021
Q1 		$916K Sell
21,811
-1,050
-5% -$59.8K 0.01% 987
2020
Q4 		$1.6M Buy
22,861
+3,791
+20% +$156K 0.01% 753
2020
Q3 		$535K Buy
19,070
+1,850
+11% +$60.3K ﹤0.01% 1028
2020
Q2 		$509K Buy
17,220
+60
+0.3% +$1.57K ﹤0.01% 1013
2020
Q1 		$340K Sell
17,160
-3,650
-18% -$92.1K ﹤0.01% 1050
2019
Q4 		$616K Sell
20,810
-200
-1% -$5K 0.01% 1029
2019
Q3 		$478K Buy
21,010
+200
+1% +$4.95K ﹤0.01% 1105
2019
Q2 		$515K Sell
20,810
-50,000
-71% -$1.19M ﹤0.01% 1067
2019
Q1 		$1.73M Hold
70,810
– – 0.02% 661
2018
Q4 		$1.61M Sell
70,810
-500
-0.7% -$13.6K 0.02% 626
2018
Q3 		$2.27M Buy
71,310
+110
+0.2% +$3.56K 0.02% 608
2018
Q2 		$2.55M Sell
71,200
-200
-0.3% -$7.08K 0.03% 531
2018
Q1 		$2.37M Hold
71,400
– – 0.02% 553
2017
Q4 		$2.19M Buy
71,400
+49,200
+222% +$1.24M 0.02% 577
2017
Q3 		$533K Sell
22,200
-56,000
-72% -$1.07M 0.01% 1015
2017
Q2 		$1.32M Buy
+78,200
New +$1.41M 0.02% 723

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Nisa Investment Advisors's EDIT Position: Q2 2026 in Review

Nisa Investment Advisors held its Editas Medicine (EDIT) position steady in Q2 2026 at 932 shares worth $3.02K. The position accounts for ﹤0.01% of the portfolio, ranked #2690.

Nisa Investment Advisors first reported a position in EDIT in Q2 2017 and has held it in 37 quarters since. The position peaked at $2.55M in Q2 2018. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Nisa Investment Advisors held 932 shares of Editas Medicine worth $3.02K as of Q2 2026.
  • Nisa Investment Advisors left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2690 holding.
  • Nisa Investment Advisors first reported a position in Editas Medicine in Q2 2017 and has held it in 37 quarters since.
  • Nisa Investment Advisors's Editas Medicine position peaked at $2.55M in Q2 2018.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.